EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Real-world evaluation of treatment utilization by women experiencing vasomotor symptoms associated with menopause in the United States and Europe: Findings from the REALISE study

Sheryl Kingsberg, Victoria Banks, Cecilia Caetano, Cecile Janssenswillen, Carsten Moeller, Nils Schoof, Mia Harvey, Megan Scott, Rossella E Nappi

Maturitas · 2024

DOI: 10.1016/j.maturitas.2024.108096 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Maturitas, 2024. Verfasst von Sheryl Kingsberg und 8 weiteren Autor:innen. Beteiligte Einrichtung: University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, United States. Electronic address: Sheryl.Kingsber…. Hauptthemen laut MEDLINE: Menopause, Hot Flashes, Nonprescription Drugs. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bayer AG.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Despite the profound impact of menopausal symptoms on women, treatment utilization is low, and many seek alternative therapies. The REALISE study aimed to evaluate the treatment landscape - that is, pharmacological treatment, lifestyle changes (LC), and use of over-the-counter (OTC) products - for women from six high-income countries experiencing vasomotor symptoms (VMS) and receiving healthcare. STUDY DESIGN: Analysis of a secondary dataset, the Adelphi Real World Disease Specific Programme™, a large, cross-sectional, point-in-time survey conducted in the United States and five European countries (February-October 2020). Physicians provided demographic, clinical, and treatment data; women were stratified by VMS severity (mild; moderate-severe) and presence of concomitant sleep/mood symptoms. Women completed forms on VMS severity, concomitant symptoms, LC, and OTC product use. Two subgroups were identified: VMS-only and VMS + sleep/mood. MAIN OUTCOME MEASURES: Prescription treatment, LC, and OTC product utilization. RESULTS: Physicians (n = 233) provided data on 1767 women; 825 (46.7 %) completed a self-completion form. Physicians rated 60 % of women with moderate-severe VMS, of whom 709 (66.8 %) were currently prescribed pharmacological treatment; 27.1 % had never been prescribed. Hormone therapy was most frequently prescribed in the moderate-severe group (overall, 49.8 %; VMS-only, 57.4 %; VMS + sleep/mood, 47.3 %), followed by serotonergic antidepressants (15.7 %; 9.7 %; 17.6 %, respectively). Most women (78.3 %) with moderate-severe VMS adopted LC, and 57.6 % used at least one OTC product for VMS relief. CONCLUSIONS: Nearly a third of women with moderate-severe VMS had never received treatment despite access to healthcare. This, combined with the prevalent use of LC/OTC products, suggests an unmet need for new treatment options to manage VMS and concomitant sleep/mood symptoms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MenopauseHot FlashesNonprescription DrugsHumansFemaleUnited StatesEuropeMiddle AgedCross-Sectional StudiesAdultLife StyleAgedSeverity of Illness Index

Stichwörter der Autor:innen

Complementary alternative medicine (CAM)DepressionDrug utilizationMenopauseSleepVasomotor symptoms (VMS)

Substanzen

Nonprescription Drugs

Autor:innen und Institutionen

  • University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, United States. Electronic address: Sheryl.Kingsberg@UHhospitals.org.
  • Bayer, Reading, United Kingdom.
  • Bayer Consumer Care, Basel, Switzerland.
  • Bayer AG, Berlin, Germany.
  • Adelphi Real World, Bollington, United Kingdom.
  • Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy; Research Center for Reproductive Medicine, Gynecological Endocrinology and Menopause, Obstetrics and Gynecology Uni…

Förderung

  • Bayer AG

Zitieren

APA

Kingsberg, S., Banks, V., Caetano, C., Janssenswillen, C., Moeller, C., Schoof, N., Harvey, M., Scott, M., & Nappi, R. E. (2024). Real-world evaluation of treatment utilization by women experiencing vasomotor symptoms associated with menopause in the United States and Europe: Findings from the REALISE study. Maturitas. https://doi.org/10.1016/j.maturitas.2024.108096

Vancouver

Kingsberg S, Banks V, Caetano C, Janssenswillen C, Moeller C, Schoof N, et al. Real-world evaluation of treatment utilization by women experiencing vasomotor symptoms associated with menopause in the United States and Europe: Findings from the REALISE study. Maturitas. 2024. doi:10.1016/j.maturitas.2024.108096

BibTeX
@article{Kingsberg2024,
  author = {Kingsberg, Sheryl and Banks, Victoria and Caetano, Cecilia and Janssenswillen, Cecile and Moeller, Carsten and Schoof, Nils and Harvey, Mia and Scott, Megan and Nappi, Rossella E},
  title = {Real-world evaluation of treatment utilization by women experiencing vasomotor symptoms associated with menopause in the United States and Europe: Findings from the REALISE study},
  journal = {Maturitas},
  year = {2024},
  doi = {10.1016/j.maturitas.2024.108096}
}
Kostenlos starten →